Tempest Therapeutics
TPST
30 hedge funds and large institutions have $53.2M invested in Tempest Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 16 closing their positions.
5,830% more capital inflows, than outflows
Capital inflows: $66.5M | Capital outflows: $1.12M
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
29.6% more ownership
Funds ownership: 22.57% → 52.16% (+30%)
14% less funds holding
Funds holding: 35 → 30 (-5)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NEA Management Company
Timonium,
Maryland
|
+$18.6M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$14.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.6M |
| 4 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$4.85M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$401K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$187K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$140K |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
-$109K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$49K |
TPST Hedge Fund Activity: Q4 2018 in Review
30 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2018, worth a combined $53.2M — up 803% from $5.89M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of TPST and 11 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was NEA Management Company, opening a new position worth an estimated $18.6M. The largest seller was Vanguard Group, cutting an estimated $401K.
- 30 institutional investors held Tempest Therapeutics (TPST) as of Q4 2018, down from 35 in Q3 2018.
- Funds reported $53.2M of Tempest Therapeutics stock for Q4 2018, up 803% quarter-over-quarter.
- 11 funds opened new Tempest Therapeutics positions in Q4 2018 and 16 closed out, a net change of -5 holders.
- The largest Tempest Therapeutics buyer in Q4 2018 was NEA Management Company, an estimated $18.6M added.
- The largest Tempest Therapeutics seller in Q4 2018 was Vanguard Group, an estimated $401K sold.
Based on aggregated 13F filings for Q4 2018.